Can transient protein expression transform #bioproduction? In his @GENbio byline, MaxCyte CSO Cenk Sumen, Ph.D. suggests its efficiencies could help drive the development of cell therapies to treat muscular dystrophy, Parkinson’s, diabetes and beyond. https://www.genengnews.com/topics/bioprocessing/transient-protein-expression-will-revolutionize-bioproduction/

Precision genome engineering requires efficient & reproducible reagent delivery. In our case study, we share data on gene correction in patient-derived cells following transfection of CRISPR-Cas9 with repair template using our #electroporation technology. https://maxcyte.com/case-study-ex-vivo-gene-correction-in-x-cgd-patient-stem-cells/

What do you need to advance the development and manufacturing of your cell-based therapy? Discover how to transform delicate cells into powerful medicines with MaxCyte's leading non-viral cell engineering platform. Watch now: http://www.maxcyte.com

Many transient gene expression (TGE) methods produce insufficient protein quantities. Our flow electroporation provides efficient TGE for rapid production of large-scale quantities of proteins, antibodies, VLPs, & vaccines. Learn more: https://maxcyte.com/scalable-protein-production-using-flow-electroporation-3/

In honor of #WorldLungCancerDay, MaxCyte is striving to raise awareness. We are dedicated to advancing cell engineering with our best-in-class electroporation platform, which our customers use to accelerate the development of T cell therapies for solid tumors.